{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T23:31:26Z","timestamp":1684971086769},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1007\/s11906-007-0069-4","type":"journal-article","created":{"date-parts":[[2007,10,3]],"date-time":"2007-10-03T07:19:08Z","timestamp":1191395948000},"page":"373-379","source":"Crossref","is-referenced-by-count":4,"title":["Renal protection: Are all antihypertensive drugs comparable?"],"prefix":"10.1007","volume":"9","author":[{"given":"Rashida","family":"Blake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leopoldo","family":"Raij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivonne Hernandez","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,4]]},"reference":[{"key":"69_CR1","first-page":"1","volume":"42","author":"USRDS","year":"2003","unstructured":"USRDS: The United States Renal Data System. Am J Kidney Dis 2003, 42:1\u2013230.","journal-title":"Am J Kidney Dis"},{"key":"69_CR2","doi-asserted-by":"crossref","first-page":"112S","DOI":"10.1016\/j.amjhyper.2004.11.046","volume":"18","author":"G.L. Bakris","year":"2005","unstructured":"Bakris GL: Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens 2005, 18:112S\u2013119S.","journal-title":"Am J Hypertens"},{"key":"69_CR3","doi-asserted-by":"crossref","first-page":"100S","DOI":"10.1016\/j.amjhyper.2004.11.017","volume":"18","author":"M.R. Weir","year":"2005","unstructured":"Weir MR: The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. Am J Hypertens 2005, 18:100S\u2013105S.","journal-title":"Am J Hypertens"},{"key":"69_CR4","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"A.V. Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560\u20132572.","journal-title":"JAMA"},{"key":"69_CR5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1210\/er.2003-0001","volume":"24","author":"R.M. Carey","year":"2003","unstructured":"Carey RM, Siragy HM: Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003, 24:261\u2013271.","journal-title":"Endocr Rev"},{"key":"69_CR6","doi-asserted-by":"crossref","unstructured":"Remuzzi G, Perico N, Macia M, Ruggenenti P: The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005:S57\u201365.","DOI":"10.1111\/j.1523-1755.2005.09911.x"},{"key":"69_CR7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/01.RES.61.4.531","volume":"61","author":"T. Yoshioka","year":"1987","unstructured":"Yoshioka T, Rennke HG, Salant DJ, et al.: Role of abnormally high transmural pressure in the permselectivity defect of glomerular capillary wall: a study in early passive Heymann nephritis. Circ Res 1987, 61:531\u2013538.","journal-title":"Circ Res"},{"key":"69_CR8","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","volume":"35","author":"Y. Sun","year":"2000","unstructured":"Sun Y, Zhang J, Zhang JQ, Ramires FJ: Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 2000, 35:1078\u20131084.","journal-title":"Hypertension"},{"key":"69_CR9","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"E.J. Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456\u20131462.","journal-title":"N Engl J Med"},{"key":"69_CR10","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1172\/JCI112528","volume":"77","author":"S. Anderson","year":"1986","unstructured":"Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986, 77:1993\u20132000.","journal-title":"J Clin Invest"},{"key":"69_CR11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0002-9343(85)90078-6","volume":"79","author":"L. Raij","year":"1985","unstructured":"Raij L, Chiou XC, Owens R, Wrigley B: Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model. Am J Med 1985, 79:37\u201341.","journal-title":"Am J Med"},{"key":"69_CR12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/BF00403306","volume":"39","author":"The Microalbuminuria Captopril Study Group","year":"1996","unstructured":"The Microalbuminuria Captopril Study Group: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996, 39:587\u2013593.","journal-title":"Diabetologia"},{"key":"69_CR13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"E.J. Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851\u2013860.","journal-title":"N Engl J Med"},{"key":"69_CR14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"B.M. Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861\u2013869.","journal-title":"N Engl J Med"},{"key":"69_CR15","doi-asserted-by":"crossref","unstructured":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43:S1\u2013290.","DOI":"10.1053\/j.ajkd.2004.03.003"},{"key":"69_CR16","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","volume":"351","author":"A.H. Barnett","year":"2004","unstructured":"Barnett AH, Bain SC, Bouter P, et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952\u20131961.","journal-title":"N Engl J Med"},{"key":"69_CR17","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1681\/ASN.2005121324","volume":"17","author":"G. Remuzzi","year":"2006","unstructured":"Remuzzi G, Macia M, Ruggenenti P: Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006, 17:S90\u201397.","journal-title":"J Am Soc Nephrol"},{"key":"69_CR18","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","volume":"351","author":"P. Ruggenenti","year":"2004","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, et al.: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941\u20131951.","journal-title":"N Engl J Med"},{"key":"69_CR19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0272-6386(89)80129-5","volume":"13","author":"L.M. Ruilope","year":"1989","unstructured":"Ruilope LM, Miranda B, Morales JM, et al.: Converting enzyme inhibition in chronic renal failure. Am J Kidney Dis 1989, 13:120\u2013126.","journal-title":"Am J Kidney Dis"},{"key":"69_CR20","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"J.T. Wright Jr","year":"2002","unstructured":"Wright JT Jr, Bakris G, Greene T, et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421\u20132431.","journal-title":"JAMA"},{"key":"69_CR21","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/archinte.162.14.1636","volume":"162","author":"J.T. Wright Jr","year":"2002","unstructured":"Wright JT Jr, Agodoa L, Contreras G, et al.: Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002, 162:1636\u20131643.","journal-title":"Arch Intern Med"},{"key":"69_CR22","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","author":"The GISEN Group","year":"1997","unstructured":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of rampiril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997, 349:1857\u20131863.","journal-title":"Lancet"},{"key":"69_CR23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","volume":"361","author":"N. Nakao","year":"2003","unstructured":"Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117\u2013124.","journal-title":"Lancet"},{"key":"69_CR24","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2007.02097.x","volume":"24","author":"D.L. Jennings","year":"2007","unstructured":"Jennings DL, Kalus JS, Coleman CI, et al.: Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007, 24:486\u2013493.","journal-title":"Diabet Med"},{"key":"69_CR25","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","volume":"14","author":"T.H. Hostetter","year":"2003","unstructured":"Hostetter TH, Ibrahim HN: Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 2003, 14:2395\u20132401.","journal-title":"J Am Soc Nephrol"},{"key":"69_CR26","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","volume":"119","author":"M. Epstein","year":"2006","unstructured":"Epstein M: Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006, 119:912\u2013919.","journal-title":"Am J Med"},{"key":"69_CR27","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","volume":"58","author":"N.J. Brown","year":"2000","unstructured":"Brown NJ, Nakamura S, Ma L, et al.: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000, 58:1219\u20131227.","journal-title":"Kidney Int"},{"key":"69_CR28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","volume":"18","author":"A. Sato","year":"2005","unstructured":"Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005, 18:44\u201349.","journal-title":"Am J Hypertens"},{"key":"69_CR29","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","volume":"47","author":"K.J. Schjoedt","year":"2004","unstructured":"Schjoedt KJ, Andersen S, Rossing P, et al.: Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004, 47:1936\u20131939.","journal-title":"Diabetologia"},{"key":"69_CR30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M. Epstein","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M, et al.: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940\u2013951.","journal-title":"Clin J Am Soc Nephrol"},{"key":"69_CR31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.HYP.0000253780.36691.4f","volume":"49","author":"E. O\u2019Brien","year":"2007","unstructured":"O\u2019Brien E, Barton J, Nussberger J, et al.: Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007, 49:276\u2013284.","journal-title":"Hypertension"},{"key":"69_CR32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11906-007-0024-4","volume":"9","author":"Y. Huang","year":"2007","unstructured":"Huang Y, Border WA, Noble NA: Functional renin receptors in renal mesangial cells. Curr Hypertens Rep 2007, 9:133\u2013139.","journal-title":"Curr Hypertens Rep"},{"key":"69_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2007.01.016","volume":"74","author":"D.J. Triggle","year":"2007","unstructured":"Triggle DJ: Calcium channel antagonists: clinical uses\u2014past, present and future. Biochem Pharmacol 2007, 74:1\u20139.","journal-title":"Biochem Pharmacol"},{"key":"69_CR34","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT OfficersCoordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981\u20132997.","journal-title":"JAMA"},{"key":"69_CR35","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S. Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022\u20132031.","journal-title":"Lancet"},{"key":"69_CR36","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","volume":"290","author":"C.J. Pepine","year":"2003","unstructured":"Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805\u20132816.","journal-title":"JAMA"},{"key":"69_CR37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1023\/A:1007882624572","volume":"14","author":"S. Koshy","year":"2000","unstructured":"Koshy S, Bakris GL: Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther 2000, 14:295\u2013301.","journal-title":"Cardiovasc Drugs Ther"},{"key":"69_CR38","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1523-1755.1998.00055.x","volume":"54","author":"A.C. Smith","year":"1998","unstructured":"Smith AC, Toto R, Bakris GL: Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998, 54:889\u2013896.","journal-title":"Kidney Int"},{"key":"69_CR39","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","volume":"65","author":"G.L. Bakris","year":"2004","unstructured":"Bakris GL, Weir MR, Secic M, et al.: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004, 65:1991\u20132002.","journal-title":"Kidney Int"},{"key":"69_CR40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0272-6386(03)00410-4","volume":"42","author":"R. Boero","year":"2003","unstructured":"Boero R, Rollino C, Massara C, et al.: The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. Am J Kidney Dis 2003, 42:67\u201375.","journal-title":"Am J Kidney Dis"},{"key":"69_CR41","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/01.CIR.97.6.576","volume":"97","author":"X. Zhang","year":"1998","unstructured":"Zhang X, Hintze TH: Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998, 97:576\u2013580.","journal-title":"Circulation"},{"key":"69_CR42","first-page":"40","volume":"17","author":"I.H. Schulman","year":"2005","unstructured":"Schulman IH, Zachariah M, Raij L: Calcium channel blockers, endothelial dysfunction, and combination therapy. Aging Clin Exp Res 2005, 17:40\u201345.","journal-title":"Aging Clin Exp Res"},{"key":"69_CR43","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/01.fjc.0000238598.09152.30","volume":"48","author":"M.S. Zhou","year":"2006","unstructured":"Zhou MS, Jaimes EA, Raij L: Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats. J Cardiovasc Pharmacol 2006, 48:857\u2013861.","journal-title":"J Cardiovasc Pharmacol"},{"key":"69_CR44","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1001\/archinte.164.22.2465","volume":"164","author":"K.C. Abbott","year":"2004","unstructured":"Abbott KC, Trespalacios FC, Agodoa LY, et al.: Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 2004, 164:2465\u20132471.","journal-title":"Arch Intern Med"},{"key":"69_CR45","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/sj.ki.5001835","volume":"70","author":"G.L. Bakris","year":"2006","unstructured":"Bakris GL, Hart P, Ritz E: Beta blockers in the management of chronic kidney disease. Kidney Int 2006, 70:1905\u20131913.","journal-title":"Kidney Int"},{"key":"69_CR46","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-7061(98)00141-1","volume":"11","author":"S. Jacob","year":"1998","unstructured":"Jacob S, Rett K, Henriksen EJ: Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998, 11:1258\u20131265.","journal-title":"Am J Hypertens"},{"issue":"Suppl1","key":"69_CR47","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1097\/00005344-199219001-00019","volume":"19","author":"K. Tomita","year":"1992","unstructured":"Tomita K, Marumo F: Effect of long-term carvedilol therapy on renal function in essential hypertension. J Cardiovasc Pharmacol 1992, 19(Suppl 1):S97\u2013101.","journal-title":"J Cardiovasc Pharmacol"},{"key":"69_CR48","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1161\/01.HYP.0000190585.54734.48","volume":"46","author":"G.L. Bakris","year":"2005","unstructured":"Bakris GL, Fonseca V, Katholi RE, et al.: Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005, 46:1309\u20131315.","journal-title":"Hypertension"},{"key":"69_CR49","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/01.CIR.0000066912.58385.DE","volume":"107","author":"L. Kalinowski","year":"2003","unstructured":"Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al.: Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003, 107:2747\u20132752.","journal-title":"Circulation"},{"key":"69_CR50","doi-asserted-by":"crossref","first-page":"446","DOI":"10.5414\/CNP63446","volume":"63","author":"D. Jovanovic","year":"2005","unstructured":"Jovanovic D, Jovovic D, Mihailovic-Stanojevic N, et al.: Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy. Clin Nephrol 2005, 63:446\u2013453.","journal-title":"Clin Nephrol"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-007-0069-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-007-0069-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-007-0069-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:14:19Z","timestamp":1559434459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-007-0069-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["69"],"URL":"https:\/\/doi.org\/10.1007\/s11906-007-0069-4","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}